60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire
60 Degrees Pharmaceuticals licensed Australian chestnut extract for non-prescription botanical supplement use. This signals potential new NDI notifications and labeling requirements for products containing this ingredient.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers considering Australian chestnut extract should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; monitor for FDA announcements or enforcement actions.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
A new botanical ingredient (Australian chestnut extract) is being developed for supplement use, which may require NDI notification and compliant labeling.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers considering Australian chestnut extract
What you must do
Monitor FDA guidance on Australian chestnut extract; if you plan to use it, submit NDI notification and ensure labeling meets FDA requirements.
Deadline
No immediate deadline; monitor for FDA announcements or enforcement actions.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- Warning Letters | FDA
- FDA Advisory No.2026-0735 || Public Health Warning on the Presence of Sildenafil Citrate in TURBO Maca and Clavo Huasca Dietary Supplement Capsules for Men with Lot Number 24TRB1102 - Food and Drug Administration - fda.gov.ph
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO